Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Immunome Inc (IMNM)

Immunome Inc (IMNM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,942,418
  • Shares Outstanding, K 91,710
  • Annual Sales, $ 9,040 K
  • Annual Income, $ -292,960 K
  • EBIT $ -225 M
  • EBITDA $ -225 M
  • 60-Month Beta 2.17
  • Price/Sales 219.11
  • Price/Cash Flow N/A
  • Price/Book 7.12

Options Overview Details

View History
  • Implied Volatility 87.28% (-1.42%)
  • Historical Volatility 88.14%
  • IV Percentile 4%
  • IV Rank 3.86%
  • IV High 298.95% on 09/19/25
  • IV Low 78.77% on 01/22/25
  • Expected Move (DTE 16) 2.00 (9.30%)
  • Put/Call Vol Ratio 3.00
  • Today's Volume 188
  • Volume Avg (30-Day) 1,499
  • Put/Call OI Ratio 0.32
  • Today's Open Interest 18,292
  • Open Int (30-Day) 19,091
  • Expected Range 19.48 to 23.48

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.65
  • Number of Estimates 6
  • High Estimate -0.58
  • Low Estimate -0.75
  • Prior Year -0.84
  • Growth Rate Est. (year over year) +22.62%

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.81 +27.78%
on 12/02/25
25.30 -15.10%
on 12/15/25
+3.06 (+16.61%)
since 11/28/25
3-Month
11.25 +90.93%
on 10/02/25
25.30 -15.10%
on 12/15/25
+9.77 (+83.43%)
since 09/30/25
52-Week
5.15 +317.09%
on 04/09/25
25.30 -15.10%
on 12/15/25
+11.20 (+108.95%)
since 12/30/24

Most Recent Stories

More News
Immunome Announces Pricing of Public Offering of Common Stock

Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the pricing of an underwritten...

IMNM : 21.48 (+1.42%)
Stocks Fall Ahead of US November Payroll Report

The S&P 500 Index ($SPX ) (SPY ) on Monday closed down by -0.16%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down by -0.09%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down by -0.51%....

MSTR : 151.95 (-2.35%)
IMNM : 21.48 (+1.42%)
GLXY : 22.36 (-1.84%)
BLDR : 102.89 (-0.29%)
$IUXX : 25,249.85 (-0.84%)
COIN : 226.14 (-2.36%)
ZNH26 : 112-140s (-0.18%)
OXY : 41.12 (-0.82%)
ESH26 : 6,892.50s (-0.75%)
FANG : 150.33 (-0.61%)
LYB : 43.30 (-0.82%)
$DOWI : 48,063.29 (-0.63%)
Immunome Announces Proposed Public Offering of Common Stock

Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced its plans to commence an underwritten...

IMNM : 21.48 (+1.42%)
Stocks Turn Lower on AI Spending Concerns

The S&P 500 Index ($SPX ) (SPY ) today is down by -0.15%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down by -0.24%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down by -0.26%. December E-mini...

MSTR : 151.95 (-2.35%)
AMAT : 256.99 (-1.15%)
IMNM : 21.48 (+1.42%)
GLXY : 22.36 (-1.84%)
BLDR : 102.89 (-0.29%)
AKAM : 87.25 (-0.82%)
$IUXX : 25,249.85 (-0.84%)
COIN : 226.14 (-2.36%)
ZNH26 : 112-140s (-0.18%)
OXY : 41.12 (-0.82%)
ESH26 : 6,892.50s (-0.75%)
FANG : 150.33 (-0.61%)
Stocks Climb in Anticipation of Fed-Friendly US Economic News

The S&P 500 Index ($SPX ) (SPY ) today is up by +0.39%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up by +0.27%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up by +0.50%. December E-mini S&P futures...

TER : 193.56 (-1.58%)
AMAT : 256.99 (-1.15%)
IMNM : 21.48 (+1.42%)
B : 43.55 (-1.56%)
HL : 19.19 (-1.54%)
AKAM : 87.25 (-0.82%)
TXN : 173.49 (-1.10%)
$IUXX : 25,249.85 (-0.84%)
ASML : 1,069.86 (-0.21%)
ZNH26 : 112-140s (-0.18%)
ESH26 : 6,892.50s (-0.75%)
LYB : 43.30 (-0.82%)
Immunome Announces Positive Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors

Registrational trial met primary endpoint, with varegacestat significantly improving progression-free survival vs. placebo (hazard ratio = 0.16, p

IMNM : 21.48 (+1.42%)
Immunome to Announce Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors

Company to host webcast Monday, December 15, 2025 at 8:30 a.m. ET

IMNM : 21.48 (+1.42%)
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Immunome, Inc. (the “company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on December 1, 2025, the...

IMNM : 21.48 (+1.42%)
Immunome to Present at Upcoming Investor Conferences

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that members of Immunome’s management...

IMNM : 21.48 (+1.42%)
Immunome Reports Third Quarter 2025 Financial Results and Provides Business Update

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the quarter ended September...

IMNM : 21.48 (+1.42%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Immunome, Inc. is a biopharmaceutical company utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. Immunome, Inc. is based in Exton, United States.

See More

Key Turning Points

3rd Resistance Point 22.42
2nd Resistance Point 22.04
1st Resistance Point 21.76
Last Price 21.48
1st Support Level 21.10
2nd Support Level 20.72
3rd Support Level 20.44

See More

52-Week High 25.30
Last Price 21.48
Fibonacci 61.8% 17.60
Fibonacci 50% 15.22
Fibonacci 38.2% 12.85
52-Week Low 5.15

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar